CVM ▼ -0.6% - CEL-SCI Corporation $CVM CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival 26-OCT-2026 08:02 AM ET